AcelRx Pharma (ACRX) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
AcelRx Pharmaceuticals Provides Corporate Update and Reports First Quarter 2016 Financial Results
May 2, 2016 4:01 PM EDTREDWOOD CITY, Calif., May 2, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a business update and reported financial results for the three months ended March 31, 2016.  Â
Corporate Highlights
ARX-04 Emergency Room and Postoperative Studies: AcelRx initiated two Phase 3 studies in the first quarter of 2016. The first, an extension to the SAP302 study, is targeted to enroll up to an additional 60 patients who present to... More